Serelaxin is recombinant human relaxin-2 (RLX030) studied mainly as a short intravenous infusion in acute heart failure. After early promise, the large RELAX-AHF-2 trial did not meet its primary endpoints, and the compound remains investigational and unapproved. Human data therefore exist but are ultimately negative for its lead indication.
Mechanism under study
Recombinant relaxin-2 that agonizes the RXFP1 receptor, producing systemic and renal vasodilation, increased arterial compliance, and anti-fibrotic and anti-inflammatory signaling.
Research-reported dosing
Investigational and not approved. The RELAX-AHF program administered 30 mcg/kg/day as a continuous 48-hour intravenous infusion in acute heart failure; RELAX-AHF-2 did not meet its primary endpoints. Reported, not recommended.
Not a standard bacteriostatic-water subcutaneous injectable. It is a biologic prepared and diluted for continuous intravenous infusion in a clinical setting, not consumer-reconstituted.
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Serelaxin (Recombinant Relaxin-2) FAQ
What is Serelaxin (Recombinant Relaxin-2)?
Serelaxin is recombinant human relaxin-2 (RLX030) studied mainly as a short intravenous infusion in acute heart failure. After early promise, the large RELAX-AHF-2 trial did not meet its primary endpoints, and the compound remains investigational and unapproved. Human data therefore exist but are ultimately negative for its lead indication.
What is the half-life of Serelaxin (Recombinant Relaxin-2)?
Short circulating half-life; it was given as a continuous 48-hour intravenous infusion in trials rather than as bolus injections.
What is the research-reported dosing for Serelaxin (Recombinant Relaxin-2)?
Investigational and not approved. The RELAX-AHF program administered 30 mcg/kg/day as a continuous 48-hour intravenous infusion in acute heart failure; RELAX-AHF-2 did not meet its primary endpoints. Reported, not recommended.
How is Serelaxin (Recombinant Relaxin-2) reconstituted?
Not a standard bacteriostatic-water subcutaneous injectable. It is a biologic prepared and diluted for continuous intravenous infusion in a clinical setting, not consumer-reconstituted.
Is Serelaxin (Recombinant Relaxin-2) FDA-approved?
No — Serelaxin (Recombinant Relaxin-2) is investigational and not FDA-approved. It is sold for laboratory research use only.
References
Related peptides
B7-33
Single-chain relaxin-2 peptide analog
B7-33 is a single-chain peptide analog of human relaxin-2 engineered to retain relaxin anti-fibrotic activity in a simpler, more synthesizable molecule. It is a preclinical research reagent studied in models of cardiac, lung, and kidney fibrosis, with no human trials and no approved use.
BPC-157
Synthetic pentadecapeptide
A stable synthetic peptide based on a partial sequence identified in gastric juice. It is one of the most-studied research peptides for connective-tissue and gut-lining repair in animal models.
TB-500
Synthetic actin-binding peptide fragment
A synthetic fragment related to Thymosin Beta-4, a naturally occurring actin-regulating peptide. Studied in preclinical models for cell migration, wound healing, and flexibility.
SS-31
Mitochondria-targeting tetrapeptide
A mitochondria-targeting tetrapeptide, also known as elamipretide, studied clinically for mitochondrial diseases and other conditions involving mitochondrial dysfunction.